Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769963 · ClinicalTrials.gov registry record · NA
Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease
A NA study of Chronic Kidney Disease, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01769963: Completed NA study of Chronic Kidney Disease, sponsored by University of Alabama at Birmingham.
NCT01769963 is a NA study of Chronic Kidney Disease that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769963, a NA study of Chronic Kidney Disease, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn more about how advanced glycation end-products can affect insulin resistance, inflammation and blood vessel health in people with kidney disease.
Primary Outcome
Change in CML concentrations
Conditions Studied
Interventions
- OTHER Research diet
Study Locations (1)
Alabama
- University of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-02 |
| Phase | NA |
What the finished NCT01769963 record still lists
NCT01769963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Research diet is the first listed.
NCT01769963 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01769963 about?
NCT01769963 is a clinical study titled "Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease". The purpose of the study is to learn more about how advanced glycation end-products can affect insulin resistance, inflammation and blood vessel health in people with kidney disease.
What is the current status of trial NCT01769963?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2012-04. Estimated completion is 2014-02.
What conditions does trial NCT01769963 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT01769963?
The interventions under investigation include: Research diet (OTHER).
Who is sponsoring clinical trial NCT01769963?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769963 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01769963's enrollment target sits among peer trials
23 86th of 101 higher than 16 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
-
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
RECRUITING · NA
-
Transforming Hemodialysis-Related Vascular Access Education
RECRUITING · NA
-
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia